MCM
JNCE

MV Capital Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

MV Capital Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-500
Closed -$3K – 733
2021
Q2 		$3K Hold
500
– – ﹤0.01% 612
2021
Q1 		$5K Hold
500
– – ﹤0.01% 276
2020
Q4 		$4K Hold
500
– – ﹤0.01% 278
2020
Q3 		$4K Hold
500
– – ﹤0.01% 249
2020
Q2 		$3K Buy
+500
New +$2.7K ﹤0.01% 260

Other funds holding JNCE

PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

MV Capital Management's JNCE Position: Q3 2021 in Review

MV Capital Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2021, closing a stake of 500 shares — an estimated $3K sold.

MV Capital Management first reported a position in JNCE in Q2 2020 and held it in 5 quarters. The position peaked at $5K in Q1 2021. 115 funds tracked by Wall St. Rank hold JNCE as of Q3 2021.

  • MV Capital Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • MV Capital Management sold 500 Jounce Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $3K.
  • MV Capital Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2020 and held it in 5 quarters.
  • MV Capital Management's Jounce Therapeutics, Inc. Common Stock position peaked at $5K in Q1 2021.
  • 115 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2021.

Based on MV Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.